// App-Quantinova.ai

P-35 : An observational study of health-related quality of life (HRQoL) with electronic patient-reported outcome (ePRO) monitoring during nivolumab therapy for advanced gastric cancer as the 3rd or later line treatment: NIVO-G QoL study

Researchers

Presenter

  • H. Kawakami

Principal Investigators

  • S. Oyamada

  • Y. Horie

  • S. Fumita

  • N. Izawa

  • T. Miyaji

  • T. Kawaguchi

  • T. Yamaguchi

  • T. Nakajima

Medical Centers

  • Department of Early Clinical Development, Kyoto University Graduate School of Medicine, Kyoto, Japan

  • Tohoku University Graduate School of Medicine, Sendai, Japan

  • Department of Clinical Trial Data Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

  • Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan

  • Kindai University Faculty of Medicine, Osakasayama, Japan

  • Department of Clinical Oncology, St. Marianna University School of Medicine, Kawasaki, Japan

  • JORTC Data Center, Tokyo, Japan

  • Kindai university Nara hospital, Ikoma, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • Observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved